Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936221 · ClinicalTrials.gov registry record · Phase 2
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 385
- Enrollment target
NCT00936221: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00936221 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 385 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00936221, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 385 participants
- Enrollment target
Study Summary
To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma
Primary Outcome
Following progression survival data was collected until documentation of death, withdrawal of consent, loss to follow-up or the final data cut-off, whichever occurred first.
Interventions
- DRUG Placebo
- DRUG Dacarbazine
- DRUG AZD6244
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 385 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
What the finished NCT00936221 record still lists
NCT00936221 is an interventional study that assigns participants to a tested intervention. The registered 385 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00936221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00936221 about?
NCT00936221 is a clinical study titled "Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients". To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma
What is the current status of trial NCT00936221?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 385 participants. The study started on 2009-07. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00936221?
The interventions under investigation include: Placebo (DRUG), Dacarbazine (DRUG), AZD6244 (DRUG).
Who is sponsoring clinical trial NCT00936221?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00936221's enrollment target sits among peer trials
385 109th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373823 · 385 participants · NA
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- NCT05503173 · 385 participants · NA
Telehealth for Pain and Unhealthy Drinking Among PLWH
- NCT06226883 · 385 participants · Phase 2
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
- NCT06290063 · 385 participants · Phase 2
Cannabidiol and Older Adult Cannabis Users
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia